Hepatitis B - Pipeline Review, H1 2020

May 2020 | 503 pages | ID: H7CD2660DC6EN
Global Markets Direct

Abstracts

Hepatitis B - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B – Pipeline Review, H1 2020, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 29, 33, 1, 4, 77, 38 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 11 and 5 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hepatitis B - Overview
Hepatitis B - Therapeutics Development
Hepatitis B - Therapeutics Assessment
Hepatitis B - Companies Involved in Therapeutics Development
Hepatitis B - Drug Profiles
Hepatitis B - Dormant Projects
Hepatitis B - Discontinued Products
Hepatitis B - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatitis B, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hepatitis B - Pipeline by Abhelix LLC, H1 2020
Hepatitis B - Pipeline by Ai-biopharma SAS, H1 2020
Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H1 2020
Hepatitis B - Pipeline by AIMM Therapeutics BV, H1 2020
Hepatitis B - Pipeline by Akshaya Bio Inc, H1 2020
Hepatitis B - Pipeline by Aligos Therapeutics Inc, H1 2020
Hepatitis B - Pipeline by AlphaMab Co Ltd, H1 2020
Hepatitis B - Pipeline by Alphamab Oncology, H1 2020
Hepatitis B - Dormant Projects, H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..1), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..2), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..3), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..4), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..5), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..6), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..7), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..8), H1 2020
Hepatitis B - Dormant Projects, H1 2020 (Contd..9), H1 2020
Hepatitis B - Discontinued Products, H1 2020
Hepatitis B - Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatitis B, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Abhelix LLC
Ai-biopharma SAS
AiCuris GmbH & Co KG
AIMM Therapeutics BV
Akshaya Bio Inc
Aligos Therapeutics Inc
AlphaMab Co Ltd
Alphamab Oncology
Altimmune Inc
Antios Therapeutics Inc
Arbutus Biopharma Corp
Arcturus Therapeutics Ltd
Ark Biosciences Inc
Ascentage Pharma Group International
Ascletis Pharma Inc
Assembly Biosciences Inc
Atea Pharmaceuticals Inc
Aucta Pharmaceuticals LLC
Avalia Immunotherapies Ltd
Beijing Advaccine Biotechnology Company Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Minhai Biotechnology Co Ltd
Benitec Biopharma Ltd
Biological E Ltd
Biomics Biopharma Ltd
BioNet- Asia Co Ltd
Biotron Ltd
Bolder Biotechnology Inc
Bonac Corp
Brandenburg Antiinfektiva GmbH
Brickell Biotech Inc
BrightGene Bio-Medical Technology Co Ltd
Bukwang Pharm Co Ltd
Cadila Healthcare Ltd
CaroGen Corp
Casterbridge Pharmaceuticals Inc
Chengdu Hyperway Pharmaceuticals
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chong Kun Dang Pharmaceutical Corp
Chongqing Zhifei Biological Products Co Ltd
Cinkate Corp
CN Bio Innovations Ltd
Cocrystal Pharma Inc
Collaborations Pharmaceuticals Inc
CyTuVax BV
Decoy Biosystems Inc
DelSiTech Ltd
Dicerna Pharmaceuticals Inc
Dong-A Socio Holdings Co Ltd
Dynavax Technologies Corp
Elixiron Immunotherapeutics Inc
Enanta Pharmaceuticals Inc
Enochian Biosciences Inc
Enyo Pharma SA
Etna Biotech Srl
Excision BioTherapeutics Inc
F. Hoffmann-La Roche Ltd
FortuneRock (China) Ltd
Fujian Cosunter Pharmaceutical Co Ltd
GC Pharma
GemVax & KAEL Co Ltd
GeneCure LLC
GeneScience Pharmaceuticals Co Ltd
GeoVax Labs Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Golden Biotechnology Corp
Guangxi Hebabiz Pharmaceutical Co Ltd
Guangzhou Yipinhong Pharmaceutical Co Ltd
HEC Pharm Co Ltd
Hepion Pharmaceuticals Inc
Huahui Anjian (Beijing) Biotechnology Co Ltd
Humabs BioMed SA
Huons Co Ltd
ImmuneMed Inc
Immunocore Ltd
Immunotope Inc
ImQuest Life Sciences Inc
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
ISR Immune System Regulation Holding AB
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
Kainos Medicine Inc
KinoPharma Inc
LG Chem Ltd
Ligand Pharmaceuticals Inc
Lion TCR Pte Ltd
Microbiotix Inc
MYR GmbH
Novo Medi Sciences Pvt Ltd
Nucorion Pharmaceuticals Inc
Oncolys BioPharma Inc
Palisades Therapeutics
PharmaEssentia Corp
Precision Biosciences Inc
Profarma
Profectus BioSciences Inc
Qilu Pharmaceutical Co Ltd
Regeneron Pharmaceuticals Inc
Regulus Therapeutics Inc
Replicor Inc
Rodos BioTarget GmbH
Romark Laboratories LC
Samjin Pharm Co Ltd
Sclnow Biotechnology Co Ltd
Scynexis Inc
SFA Therapeutics LLC
Shanghai Henlius Biotech Inc
Shanghai Zhimeng Biopharma Inc
Shantha Biotechnics Pvt Ltd
Shenzhen BinDeBio Ltd
Sinovac Biotech Ltd
SL VaxiGen Inc
Staidson BioPharma Inc
Suzhou Ribo Life Sciences Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
TaiGen Biotechnology Co Ltd
Takeda Pharmaceutical Co Ltd
TCM Biotech International Corp
TeneoBio Inc
Tetranov International Inc
Theravectys SA
THEVAX Genetics Vaccine USA Inc
Transgene SA
UBI Pharma Inc
Vaccitech Ltd
Vaxart Inc
Vaxine Pty Ltd
VBI Vaccines Inc
VenatoRx Pharmaceuticals Inc
Vir Biotechnology Inc
Viravaxx AG
Viriom Inc
Virion Therapeutics LLC
Virocovax
ViroStatics SRL
VLP Biotech Inc
Xi’an Xintong Pharmaceutical Research Co Ltd
Yisheng Biopharma Co Ltd